Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab (CROSBI ID 306162)
Prilog u časopisu | Pismo uredniku | međunarodna recenzija
Podaci o odgovornosti
Adamec, Ivan ; Mayer, Miroslav ; Ćorić, Marijana ; Ruška, Berislav ; Habek, Mario
engleski
Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab
Alemtuzumab is a humanized monoclonal antibody targeting CD52 protein that has shown great efficacy in the treatment of relapsing remitting multiple sclerosis and is associated with prolonged remission of the disease. Although it is highly effective, alemtuzumab can lead to serious adverse advents among which the most common are secondary autoimmune diseases. We present a patient who was treated with alemtuzumab for relapsing remitting multiple sclerosis. Her disease remained stable in a follow-up period of over ten years. However, during the follow-up period she developed thyroiditis one year, as well as systemic erythematous lupus seven years after the last alemtuzumab infusion, a disease not previously associated with alemtuzumab administration.
systemic lupus ; multiple sclerosis ; alemtuzumab ; treatment
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
46
2020.
102589
3
objavljeno
2211-0348
2211-0356
10.1016/j.msard.2020.102589
Povezanost rada
Farmacija, Kliničke medicinske znanosti